Bernstein Downgrades Alnylam Pharmaceuticals to Market Perform
Bernstein has downgraded Alnylam Pharmaceuticals (ALNY) from Outperform to Market Perform. The decision, led by analyst Jeffrey Walch, stems from concerns regarding the clinical trial design of the company's next-generation RNAi therapeutic, nucresiran. Specifically, the downgrade focuses on the TRITON-CM Phase 3 trial. This shift in outlook has placed downward pressure on Alnylam's stock as investors reassess the development path and potential success of its upcoming RNAi pipeline.
Tickers: $ALNY
Topics: Clinical Trial Design RNAi Therapeutics Stock Downgrade